Stockreport

AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why [Yahoo! Finance]

AN2 Therapeutics, Inc.  (ANTX) 
US:NYSE Investor Relations: ir.antheminc.com
PDF The company is currently evaluating its lead clinical-stage candidate, epetraborole, a bacterial leucyl-tRNA synthetase inhibitor, for nontuberculous mycobacteria (NTM) [Read more]